Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-10-08
2000-06-27
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
548244, 548245, 548246, A61K 3142, C07D26112, C07D26114
Patent
active
060807741
ABSTRACT:
Compounds of the formula ##STR1## inhibit the activity of endothelin. The symbols are defined as follows: ##STR2## R.sup.2 and R.sup.3 are each independently (a) hydrogen;
REFERENCES:
patent: 2888455 (1959-05-01), Kano et al.
patent: 4415496 (1983-11-01), Harris et al.
patent: 4661479 (1987-04-01), Wyvratt, Jr. et al.
patent: 5236928 (1993-08-01), Chakravarty et al.
patent: 5270313 (1993-12-01), Burri et al.
patent: 5292740 (1994-03-01), Burri et al.
patent: 5378715 (1995-01-01), Stein et al.
patent: 5464853 (1995-11-01), Chan et al.
patent: 5514691 (1996-05-01), Chan et al.
patent: 5514696 (1996-05-01), Murugesan et al.
patent: 5571821 (1996-11-01), Chan et al.
patent: 5591761 (1997-01-01), Chan et al.
patent: 5594021 (1997-01-01), Chan et al.
patent: 5612359 (1997-03-01), Murugesan
S. Norio et al., Chemical Abstracts, vol. 70, No. 19, (1969), 87639g.
T. Saito, Chemical Abstracts, vol. 73, No. 23 (1970), 120511w.
Derwent Abstract No. 88-289069/41 Feb. 27, 1987.
Derwent Abstract No. 88-195835/28 Nov. 26, 1986.
Derwent Abstract No. 88-061295/09 Jul. 9, 1986.
Derwent Abstract No. 87-152485/22 Oct. 11, 1985.
Derwent Abstract No. 62299 E/30 Dec. 11, 1980.
Derwent Abstract No. 40927 D/23 Sep. 11, 1979.
Derwent Abstract No. 91-254550/35 Feb. 19, 1990.
Derwent Abstract No. 86-246709/38 Nov. 27, 1985.
Derwent Abstract No. 35012 K/15 Sep. 24, 1981.
Allen et al., "Preparation . . . antagonists", CA116(11):106284Z, p. 778, 1992.
R.D. Desai et al., Chemical Abstracts, vol. 71, No. 11, (1969) 49825c.
R.D. Desai et al., Chemical Abstracts, vol. 71, No. 3, (1969) 12872q.
P. G. Ferrini et al., Angew. Chem. Internat. Edit., vol. 2, No. 2 (1963) p. 99.
A. M. van Leusen, et al., "Synthesis . . . Compounds", J. Org. Chem., vol. 41, No. 4, (1976), pp. 69-71.
W. J. Hammar et al., J. Heterocyclic Chem., vol. 18, (1981) pp. 885-888.
A. M. van Leusen et al., Tetrahedron Letters, No. 23, (1972), pp. 2369-2372.
Chan et al., "Identification of a New Class of ET.sub.A Selective Endothelin Antagonists by Pharmacophore Directed Screening", Biochemical and Biophysical Research Communications, vol. 201, No. 1, May 30, 1994, pp. 228-234.
Stein et al., "The Discovery of Sulfonamide Endothelin Antagonists and the Development of the Orally Active ET.sub.A Antagonist 5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide", J. Med. Chem., vol. 37, No. 3, Feb. 4, 1994, pp. 329-331.
Doherty, J. Med. Chem., 35(9), 1493-1508 (May 1992).
CA 65: 2241d (1966).
CA 92:41908v (1979).
Wang et al., "Nitrile . . . sinomin," CA 108:94444w, p. 651 (1988).
Khanna, "Oral . . . formulation," CA 115:35728p, p. 415 (1991).
Stein et al., "The Discovery . . . 1-naphthalenesulfonamide," CA 120:18233n, p. 21-22 (1994).
Vree et al., "Renal excretion . . . function," CA 97:84685r, p. 23 (1982).
Oie, "Pharmacokinetics . . . dosing," CA 102:197512x, p. 18 (1985).
Murugesan et al., "N-(heteroaryl) . . . antagonists," CA 120:270370c, p. 1067 (1994).
Barrish Joel C.
Lloyd John
Murugesan Natesan
Babajko Suzanne E.
Balasubramanian V
Bristol--Myers Squibb Company
Hermenau Ronald S.
Shah Mukund J.
LandOfFree
Substituted biphenylsulfonamide endothelin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted biphenylsulfonamide endothelin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted biphenylsulfonamide endothelin antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1785118